Cite

HARVARD Citation

    Voss, M. et al. (2019). A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 125 (14), pp. 2400-2408. [Online]. 
  
Back to record